Intercure Ltd.
InterCure Ltd. engages in research, cultivation, production, and distribution of pharmaceutical-grade cannabis products for medical use. Subsidiaries offer dried cannabis inflorescences and cannabis extract mixed with oil. The company also invests in the biomed sector. Founded in 1994, InterCure is headquartered in Herzliya, Israel.
Overview
Strengths
- Skin in the game: insiders own 39% of the shares, aligning management with shareholders.
- Paying down debt: long-term debt fell by 6.3 percentage points of total assets last year.
Weaknesses
- No sign of a competitive advantage: return on invested capital (latest 3.0%) has been below its cost of capital of 7.3% in each of the last 6 years.
- Operating profit does not cover interest expense.
- Our discounted cash flow model finds no value to support the current price: operating profit does not cover interest expense.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Unreliable cash generation: free cash flow was negative in 3 of the last 6 years.
- High leverage: net debt is 5.3x EBITDA, against a median of 1.4x for its Drug Manufacturers - Specialty & Generic peers.
Key Financial Data